Micron Technology has delivered an impressive outlook for the current quarter, surpassing expectations with a sharp increase in revenue. The memory-chip manufacturer attributes this success to robust pricing and the growing demand for chips used in artificial intelligence applications. Despite expectations of a loss, Micron Technology reported a narrower-than-expected deficit. As a result, shares surged by 4.3% after-hours, reaching $82.11.
Warner Bros. Discovery and Paramount Explore Potential Merger
Recently, Warner Bros. Discovery Chief Executive David Zaslav and Paramount CEO Bob Bakish held discussions regarding a potential merger between the two companies. Although there have been no formal negotiations at this point, their meeting has sparked speculation about a possible collaboration. Following the news, Warner Bros. Discovery shares experienced a slight decline of 1.6% after-hours, while Paramount shares sank 1.7%.
Calliditas Therapeutics Receives FDA Approval for Tarpeyo
Calliditas Therapeutics has achieved full approval from the U.S. Food and Drug Administration (FDA) for its treatment, Tarpeyo, developed for patients diagnosed with primary immunoglobulin A nephropathy (IgAN) - a kidney disease. This marks a significant milestone as Tarpeyo becomes the first FDA-approved treatment specifically designed for IgAN patients, offering a measure of kidney function improvement. Consequently, shares soared by 25% after-hours, amounting to $28.
Broker Accused of Unregistered Payments
Related Articles
Abingdon Health Reports Narrowed Pretax Loss and Increased Revenue
Abingdon Health, a UK diagnostics company, narrows pretax loss and increases revenue due to commercial momentum and cost reduction. The company has a strong fin...
Braskem Faces Challenges with Net Loss and Sales Decline
Braskem, the Brazilian chemical company, experienced a 2.6% decrease in its shares following the announcement of a net loss and a drop in sales. The company's p...
Revolution Medicines to Acquire EQRx in $1 Billion Deal
Revolution Medicines, a clinical-stage oncology company, is set to acquire EQRx in an all-stock deal worth $1 billion.